Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:DRUGNASDAQ:MLYSNASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$29.93+0.1%$28.86$23.23▼$42.29$961.71M0.63398,915 shs315,470 shsDRUGBright Minds Biosciences$23.27-6.1%$29.56$0.93▼$79.02$163.91M-5.75828,351 shs627,261 shsMLYSMineralys Therapeutics$13.71-2.1%$14.88$8.24▼$18.38$893.55M-0.17539,476 shs2.23 million shsNTLAIntellia Therapeutics$9.56-0.5%$8.56$5.90▼$28.18$990.25M2.142.92 million shs4.00 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+0.10%+0.34%+3.53%+0.74%-5.97%DRUGBright Minds Biosciences-6.09%-14.79%-14.92%-36.25%+2,095.28%MLYSMineralys Therapeutics-2.07%+1.71%-13.45%-6.48%+23.62%NTLAIntellia Therapeutics-0.52%+3.91%-1.04%+18.46%-58.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical3.9525 of 5 stars3.41.00.03.01.40.82.5DRUGBright Minds Biosciences3.115 of 5 stars3.63.00.00.03.82.50.0MLYSMineralys Therapeutics2.1094 of 5 stars3.41.00.00.01.54.20.0NTLAIntellia Therapeutics4.6552 of 5 stars4.33.00.04.71.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7546.17% UpsideDRUGBright Minds Biosciences 3.25Buy$83.25257.76% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25135.23% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$33.37249.04% UpsideCurrent Analyst Ratings BreakdownLatest DRUG, COLL, MLYS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.006/16/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.006/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.52$12.37 per share2.42$7.10 per share4.22DRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANTLAIntellia Therapeutics$57.88M17.11N/AN/A$8.56 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.2224.534.97N/A6.61%99.08%15.14%8/6/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)Latest DRUG, COLL, MLYS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.301.081.01DRUGBright Minds BiosciencesN/A126.01126.01MLYSMineralys TherapeuticsN/A26.4826.48NTLAIntellia TherapeuticsN/A4.904.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/ADRUGBright Minds Biosciences40.52%MLYSMineralys Therapeutics84.46%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%DRUGBright Minds Biosciences42.66%MLYSMineralys Therapeutics25.56%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableMLYSMineralys Therapeutics2865.18 million48.52 millionOptionableNTLAIntellia Therapeutics600103.58 million100.37 millionOptionableDRUG, COLL, MLYS, and NTLA HeadlinesRecent News About These CompaniesCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - NasdaqJune 27 at 4:48 PM | nasdaq.comNTLA - Intellia Therapeutics Inc Chart - MorningstarJune 26 at 8:14 PM | morningstar.comMCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?June 25 at 11:05 AM | zacks.comIntellia Therapeutics, Inc. (NTLA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNTLA Intellia Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comIntellia Therapeutics (NASDAQ:NTLA) Trading Down 6.4% - Here's What HappenedJune 22, 2025 | americanbankingnews.comWill Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?June 21, 2025 | finance.yahoo.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4% - What's Next?June 20, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside PotentialJune 19, 2025 | finance.yahoo.comWedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)June 18, 2025 | theglobeandmail.comIntellia Therapeutics (NASDAQ:NTLA) Earns Neutral Rating from WedbushJune 18, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Intellia Therapeutics (NASDAQ:NTLA)June 18, 2025 | americanbankingnews.comIntellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside PotentialJune 17, 2025 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's WhyJune 17, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from WedbushJune 16, 2025 | marketbeat.com6NTLA : Assessing Intellia Therapeutics: Insights From 9 Financial...June 16, 2025 | benzinga.comIntellia Therapeutics' (NTLA) Buy Rating Reaffirmed at HC WainwrightJune 16, 2025 | marketbeat.comIntellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology CongressJune 15, 2025 | globenewswire.comBrokers Issue Forecasts for NTLA FY2026 EarningsJune 10, 2025 | marketbeat.comIntellia Therapeutics Inc.June 9, 2025 | barrons.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 8.7% - Should You Buy?June 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWith Novo Nordisk's CEO Out, Wall Street Wants an American LeaderBy Leo Miller | June 7, 2025View With Novo Nordisk's CEO Out, Wall Street Wants an American LeaderAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksTesla Bulls and Bears Collide: What Investors Should KnowBy Sam Quirke | June 18, 2025View Tesla Bulls and Bears Collide: What Investors Should KnowNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIABy Leo Miller | June 12, 2025View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIADRUG, COLL, MLYS, and NTLA Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$29.93 +0.03 (+0.10%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$29.92 -0.02 (-0.05%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Bright Minds Biosciences NASDAQ:DRUG$23.27 -1.51 (-6.09%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$24.39 +1.12 (+4.83%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Mineralys Therapeutics NASDAQ:MLYS$13.71 -0.29 (-2.07%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$13.72 +0.01 (+0.07%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Intellia Therapeutics NASDAQ:NTLA$9.56 -0.05 (-0.52%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$9.61 +0.05 (+0.51%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
